WO2000012700A1 - GENE CODIANT CDw108 - Google Patents
GENE CODIANT CDw108 Download PDFInfo
- Publication number
- WO2000012700A1 WO2000012700A1 PCT/JP1999/004571 JP9904571W WO0012700A1 WO 2000012700 A1 WO2000012700 A1 WO 2000012700A1 JP 9904571 W JP9904571 W JP 9904571W WO 0012700 A1 WO0012700 A1 WO 0012700A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- cdwl08
- polynucleotide
- cdw108
- fragment
- expression
- Prior art date
Links
- 108090000623 proteins and genes Proteins 0.000 title abstract description 46
- 101000739767 Homo sapiens Semaphorin-7A Proteins 0.000 title abstract description 8
- 102100037545 Semaphorin-7A Human genes 0.000 title abstract description 8
- 108091033319 polynucleotide Proteins 0.000 claims abstract description 73
- 102000040430 polynucleotide Human genes 0.000 claims abstract description 73
- 239000002157 polynucleotide Substances 0.000 claims abstract description 73
- 239000012634 fragment Substances 0.000 claims abstract description 43
- 108091034117 Oligonucleotide Proteins 0.000 claims abstract description 27
- 238000000034 method Methods 0.000 claims abstract description 24
- 108090000765 processed proteins & peptides Proteins 0.000 claims abstract description 21
- 239000003153 chemical reaction reagent Substances 0.000 claims abstract description 18
- 239000013604 expression vector Substances 0.000 claims abstract description 18
- 102000007056 Recombinant Fusion Proteins Human genes 0.000 claims abstract description 17
- 108010008281 Recombinant Fusion Proteins Proteins 0.000 claims abstract description 17
- 229920001184 polypeptide Polymers 0.000 claims abstract description 16
- 102000004196 processed proteins & peptides Human genes 0.000 claims abstract description 16
- 201000010099 disease Diseases 0.000 claims abstract description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims abstract description 10
- 239000004480 active ingredient Substances 0.000 claims abstract description 8
- 125000003275 alpha amino acid group Chemical group 0.000 claims description 21
- 150000001413 amino acids Chemical class 0.000 claims description 18
- 239000002773 nucleotide Substances 0.000 claims description 14
- 125000003729 nucleotide group Chemical group 0.000 claims description 14
- 238000007792 addition Methods 0.000 claims description 13
- 238000012217 deletion Methods 0.000 claims description 13
- 230000037430 deletion Effects 0.000 claims description 13
- 238000003780 insertion Methods 0.000 claims description 13
- 230000037431 insertion Effects 0.000 claims description 13
- 238000006467 substitution reaction Methods 0.000 claims description 13
- 239000008194 pharmaceutical composition Substances 0.000 claims description 11
- 238000004519 manufacturing process Methods 0.000 claims description 10
- 230000009471 action Effects 0.000 claims description 4
- 230000000295 complement effect Effects 0.000 claims description 3
- 239000002253 acid Substances 0.000 claims description 2
- 102000004169 proteins and genes Human genes 0.000 abstract description 17
- 239000013598 vector Substances 0.000 abstract description 12
- 230000008569 process Effects 0.000 abstract description 3
- 239000000203 mixture Substances 0.000 abstract 1
- 210000004027 cell Anatomy 0.000 description 60
- 230000014509 gene expression Effects 0.000 description 50
- 239000002299 complementary DNA Substances 0.000 description 40
- 241000699666 Mus <mouse, genus> Species 0.000 description 31
- 108020004999 messenger RNA Proteins 0.000 description 28
- 238000004458 analytical method Methods 0.000 description 19
- 210000001519 tissue Anatomy 0.000 description 19
- 210000001541 thymus gland Anatomy 0.000 description 17
- 239000000523 sample Substances 0.000 description 16
- 108020004414 DNA Proteins 0.000 description 13
- 241000699670 Mus sp. Species 0.000 description 13
- 210000003754 fetus Anatomy 0.000 description 12
- 102100031573 Hematopoietic progenitor cell antigen CD34 Human genes 0.000 description 11
- 101000777663 Homo sapiens Hematopoietic progenitor cell antigen CD34 Proteins 0.000 description 11
- 108010004729 Phycoerythrin Proteins 0.000 description 11
- 150000007523 nucleic acids Chemical group 0.000 description 11
- 210000003819 peripheral blood mononuclear cell Anatomy 0.000 description 11
- 238000001514 detection method Methods 0.000 description 9
- MHMNJMPURVTYEJ-UHFFFAOYSA-N fluorescein-5-isothiocyanate Chemical compound O1C(=O)C2=CC(N=C=S)=CC=C2C21C1=CC=C(O)C=C1OC1=CC(O)=CC=C21 MHMNJMPURVTYEJ-UHFFFAOYSA-N 0.000 description 9
- IYMAXBFPHPZYIK-BQBZGAKWSA-N Arg-Gly-Asp Chemical group NC(N)=NCCC[C@H](N)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(O)=O IYMAXBFPHPZYIK-BQBZGAKWSA-N 0.000 description 8
- 210000001744 T-lymphocyte Anatomy 0.000 description 8
- 230000004720 fertilization Effects 0.000 description 8
- 230000001605 fetal effect Effects 0.000 description 8
- 230000035772 mutation Effects 0.000 description 8
- 108091028043 Nucleic acid sequence Proteins 0.000 description 7
- 108700026244 Open Reading Frames Proteins 0.000 description 7
- 210000004700 fetal blood Anatomy 0.000 description 7
- 238000009396 hybridization Methods 0.000 description 7
- 239000012528 membrane Substances 0.000 description 7
- 239000000047 product Substances 0.000 description 7
- 230000005855 radiation Effects 0.000 description 7
- WSFSSNUMVMOOMR-UHFFFAOYSA-N Formaldehyde Chemical compound O=C WSFSSNUMVMOOMR-UHFFFAOYSA-N 0.000 description 6
- 238000000636 Northern blotting Methods 0.000 description 6
- 210000004556 brain Anatomy 0.000 description 6
- 238000010367 cloning Methods 0.000 description 6
- 210000004072 lung Anatomy 0.000 description 6
- 210000004698 lymphocyte Anatomy 0.000 description 6
- 102000039446 nucleic acids Human genes 0.000 description 6
- 108020004707 nucleic acids Proteins 0.000 description 6
- 239000000243 solution Substances 0.000 description 6
- 210000000952 spleen Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 101710139410 1-phosphatidylinositol phosphodiesterase Proteins 0.000 description 5
- 230000004988 N-glycosylation Effects 0.000 description 5
- 102100037097 Protein disulfide-isomerase A3 Human genes 0.000 description 5
- 230000011712 cell development Effects 0.000 description 5
- 238000011161 development Methods 0.000 description 5
- 230000018109 developmental process Effects 0.000 description 5
- 238000001114 immunoprecipitation Methods 0.000 description 5
- 238000010186 staining Methods 0.000 description 5
- NHBKXEKEPDILRR-UHFFFAOYSA-N 2,3-bis(butanoylsulfanyl)propyl butanoate Chemical compound CCCC(=O)OCC(SC(=O)CCC)CSC(=O)CCC NHBKXEKEPDILRR-UHFFFAOYSA-N 0.000 description 4
- 102100037877 Intercellular adhesion molecule 1 Human genes 0.000 description 4
- 108010076504 Protein Sorting Signals Proteins 0.000 description 4
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical compound [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 4
- 230000021164 cell adhesion Effects 0.000 description 4
- 238000007796 conventional method Methods 0.000 description 4
- 238000000684 flow cytometry Methods 0.000 description 4
- 239000012139 lysis buffer Substances 0.000 description 4
- 210000000056 organ Anatomy 0.000 description 4
- 238000012163 sequencing technique Methods 0.000 description 4
- 210000001550 testis Anatomy 0.000 description 4
- 108091032973 (ribonucleotides)n+m Proteins 0.000 description 3
- KCXVZYZYPLLWCC-UHFFFAOYSA-N EDTA Chemical compound OC(=O)CN(CC(O)=O)CCN(CC(O)=O)CC(O)=O KCXVZYZYPLLWCC-UHFFFAOYSA-N 0.000 description 3
- 241000588724 Escherichia coli Species 0.000 description 3
- 102000005720 Glutathione transferase Human genes 0.000 description 3
- 108010070675 Glutathione transferase Proteins 0.000 description 3
- 241000238631 Hexapoda Species 0.000 description 3
- OKIZCWYLBDKLSU-UHFFFAOYSA-M N,N,N-Trimethylmethanaminium chloride Chemical compound [Cl-].C[N+](C)(C)C OKIZCWYLBDKLSU-UHFFFAOYSA-M 0.000 description 3
- 108020005187 Oligonucleotide Probes Proteins 0.000 description 3
- 239000012980 RPMI-1640 medium Substances 0.000 description 3
- 238000000246 agarose gel electrophoresis Methods 0.000 description 3
- 210000004102 animal cell Anatomy 0.000 description 3
- 230000000692 anti-sense effect Effects 0.000 description 3
- 239000000427 antigen Substances 0.000 description 3
- 108091007433 antigens Proteins 0.000 description 3
- 102000036639 antigens Human genes 0.000 description 3
- 230000008827 biological function Effects 0.000 description 3
- 210000000349 chromosome Anatomy 0.000 description 3
- 238000003200 chromosome mapping Methods 0.000 description 3
- 238000010586 diagram Methods 0.000 description 3
- 238000009826 distribution Methods 0.000 description 3
- 230000006870 function Effects 0.000 description 3
- 210000001161 mammalian embryo Anatomy 0.000 description 3
- 238000010369 molecular cloning Methods 0.000 description 3
- 210000005087 mononuclear cell Anatomy 0.000 description 3
- 239000002751 oligonucleotide probe Substances 0.000 description 3
- 210000002826 placenta Anatomy 0.000 description 3
- 239000013612 plasmid Substances 0.000 description 3
- 238000011160 research Methods 0.000 description 3
- 238000012216 screening Methods 0.000 description 3
- 238000002415 sodium dodecyl sulfate polyacrylamide gel electrophoresis Methods 0.000 description 3
- 210000000130 stem cell Anatomy 0.000 description 3
- 230000002992 thymic effect Effects 0.000 description 3
- 210000005253 yeast cell Anatomy 0.000 description 3
- QKNYBSVHEMOAJP-UHFFFAOYSA-N 2-amino-2-(hydroxymethyl)propane-1,3-diol;hydron;chloride Chemical compound Cl.OCC(N)(CO)CO QKNYBSVHEMOAJP-UHFFFAOYSA-N 0.000 description 2
- 241000744472 Cinna Species 0.000 description 2
- 241000699800 Cricetinae Species 0.000 description 2
- 102000004594 DNA Polymerase I Human genes 0.000 description 2
- 108010017826 DNA Polymerase I Proteins 0.000 description 2
- 238000002965 ELISA Methods 0.000 description 2
- 208000000461 Esophageal Neoplasms Diseases 0.000 description 2
- 108091060211 Expressed sequence tag Proteins 0.000 description 2
- ZHNUHDYFZUAESO-UHFFFAOYSA-N Formamide Chemical compound NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 2
- 208000031886 HIV Infections Diseases 0.000 description 2
- 101000599852 Homo sapiens Intercellular adhesion molecule 1 Proteins 0.000 description 2
- 108010064593 Intercellular Adhesion Molecule-1 Proteins 0.000 description 2
- 241001465754 Metazoa Species 0.000 description 2
- 101000739762 Mus musculus Semaphorin-7A Proteins 0.000 description 2
- 125000001429 N-terminal alpha-amino-acid group Chemical group 0.000 description 2
- 239000000020 Nitrocellulose Substances 0.000 description 2
- 239000004677 Nylon Substances 0.000 description 2
- 206010030155 Oesophageal carcinoma Diseases 0.000 description 2
- 239000013614 RNA sample Substances 0.000 description 2
- 240000004808 Saccharomyces cerevisiae Species 0.000 description 2
- 235000014680 Saccharomyces cerevisiae Nutrition 0.000 description 2
- 238000001042 affinity chromatography Methods 0.000 description 2
- 108010072041 arginyl-glycyl-aspartic acid Proteins 0.000 description 2
- 238000000376 autoradiography Methods 0.000 description 2
- 230000015572 biosynthetic process Effects 0.000 description 2
- 239000000872 buffer Substances 0.000 description 2
- 210000004899 c-terminal region Anatomy 0.000 description 2
- 239000013592 cell lysate Substances 0.000 description 2
- 239000002771 cell marker Substances 0.000 description 2
- 238000003776 cleavage reaction Methods 0.000 description 2
- 238000000432 density-gradient centrifugation Methods 0.000 description 2
- 239000003814 drug Substances 0.000 description 2
- 230000000694 effects Effects 0.000 description 2
- 230000013020 embryo development Effects 0.000 description 2
- 201000004101 esophageal cancer Diseases 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 102000006602 glyceraldehyde-3-phosphate dehydrogenase Human genes 0.000 description 2
- 108020004445 glyceraldehyde-3-phosphate dehydrogenase Proteins 0.000 description 2
- 230000001900 immune effect Effects 0.000 description 2
- 230000001939 inductive effect Effects 0.000 description 2
- 230000026045 iodination Effects 0.000 description 2
- 238000006192 iodination reaction Methods 0.000 description 2
- 238000002955 isolation Methods 0.000 description 2
- BPHPUYQFMNQIOC-NXRLNHOXSA-N isopropyl beta-D-thiogalactopyranoside Chemical compound CC(C)S[C@@H]1O[C@H](CO)[C@H](O)[C@H](O)[C@H]1O BPHPUYQFMNQIOC-NXRLNHOXSA-N 0.000 description 2
- 238000002372 labelling Methods 0.000 description 2
- 208000032839 leukemia Diseases 0.000 description 2
- 210000004185 liver Anatomy 0.000 description 2
- 210000005210 lymphoid organ Anatomy 0.000 description 2
- 239000006166 lysate Substances 0.000 description 2
- 239000003550 marker Substances 0.000 description 2
- 229920001220 nitrocellulos Polymers 0.000 description 2
- 229920001778 nylon Polymers 0.000 description 2
- 230000008506 pathogenesis Effects 0.000 description 2
- YBYRMVIVWMBXKQ-UHFFFAOYSA-N phenylmethanesulfonyl fluoride Chemical compound FS(=O)(=O)CC1=CC=CC=C1 YBYRMVIVWMBXKQ-UHFFFAOYSA-N 0.000 description 2
- 239000008363 phosphate buffer Substances 0.000 description 2
- 239000013600 plasmid vector Substances 0.000 description 2
- 238000002360 preparation method Methods 0.000 description 2
- 238000000746 purification Methods 0.000 description 2
- 238000003127 radioimmunoassay Methods 0.000 description 2
- 230000007017 scission Effects 0.000 description 2
- 210000002966 serum Anatomy 0.000 description 2
- 239000011780 sodium chloride Substances 0.000 description 2
- 239000000126 substance Substances 0.000 description 2
- 238000009281 ultraviolet germicidal irradiation Methods 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- FWMNVWWHGCHHJJ-SKKKGAJSSA-N 4-amino-1-[(2r)-6-amino-2-[[(2r)-2-[[(2r)-2-[[(2r)-2-amino-3-phenylpropanoyl]amino]-3-phenylpropanoyl]amino]-4-methylpentanoyl]amino]hexanoyl]piperidine-4-carboxylic acid Chemical compound C([C@H](C(=O)N[C@H](CC(C)C)C(=O)N[C@H](CCCCN)C(=O)N1CCC(N)(CC1)C(O)=O)NC(=O)[C@H](N)CC=1C=CC=CC=1)C1=CC=CC=C1 FWMNVWWHGCHHJJ-SKKKGAJSSA-N 0.000 description 1
- PLIKAWJENQZMHA-UHFFFAOYSA-N 4-aminophenol Chemical compound NC1=CC=C(O)C=C1 PLIKAWJENQZMHA-UHFFFAOYSA-N 0.000 description 1
- 102000007469 Actins Human genes 0.000 description 1
- 108010085238 Actins Proteins 0.000 description 1
- 108700028369 Alleles Proteins 0.000 description 1
- 108010039627 Aprotinin Proteins 0.000 description 1
- 241000272875 Ardeidae Species 0.000 description 1
- 206010003445 Ascites Diseases 0.000 description 1
- 101000798396 Bacillus licheniformis Phenylalanine racemase [ATP hydrolyzing] Proteins 0.000 description 1
- 102100022548 Beta-hexosaminidase subunit alpha Human genes 0.000 description 1
- 235000011960 Brassica ruvo Nutrition 0.000 description 1
- 101100447462 Brugia malayi G3PD gene Proteins 0.000 description 1
- VYZAMTAEIAYCRO-UHFFFAOYSA-N Chromium Chemical compound [Cr] VYZAMTAEIAYCRO-UHFFFAOYSA-N 0.000 description 1
- 108091026890 Coding region Proteins 0.000 description 1
- 241001635598 Enicostema Species 0.000 description 1
- 101710181478 Envelope glycoprotein GP350 Proteins 0.000 description 1
- 102000004190 Enzymes Human genes 0.000 description 1
- 108090000790 Enzymes Proteins 0.000 description 1
- 241000289669 Erinaceus europaeus Species 0.000 description 1
- 241000672609 Escherichia coli BL21 Species 0.000 description 1
- 241001646716 Escherichia coli K-12 Species 0.000 description 1
- 108700024394 Exon Proteins 0.000 description 1
- 102000016359 Fibronectins Human genes 0.000 description 1
- 108010067306 Fibronectins Proteins 0.000 description 1
- 108010043685 GPI-Linked Proteins Proteins 0.000 description 1
- 102000002702 GPI-Linked Proteins Human genes 0.000 description 1
- 241000287828 Gallus gallus Species 0.000 description 1
- 241000124008 Mammalia Species 0.000 description 1
- 108010090054 Membrane Glycoproteins Proteins 0.000 description 1
- 102000012750 Membrane Glycoproteins Human genes 0.000 description 1
- 108010052285 Membrane Proteins Proteins 0.000 description 1
- 102000018697 Membrane Proteins Human genes 0.000 description 1
- 206010027626 Milia Diseases 0.000 description 1
- 101800000135 N-terminal protein Proteins 0.000 description 1
- 206010028980 Neoplasm Diseases 0.000 description 1
- 101800001452 P1 proteinase Proteins 0.000 description 1
- 238000012408 PCR amplification Methods 0.000 description 1
- 239000002033 PVDF binder Substances 0.000 description 1
- 102000003992 Peroxidases Human genes 0.000 description 1
- 101100434648 Petromyzon marinus SDS-1 gene Proteins 0.000 description 1
- 108010047620 Phytohemagglutinins Proteins 0.000 description 1
- 206010035226 Plasma cell myeloma Diseases 0.000 description 1
- 108010014608 Proto-Oncogene Proteins c-kit Proteins 0.000 description 1
- 102000016971 Proto-Oncogene Proteins c-kit Human genes 0.000 description 1
- 238000002123 RNA extraction Methods 0.000 description 1
- 102000014105 Semaphorin Human genes 0.000 description 1
- 108050003978 Semaphorin Proteins 0.000 description 1
- 241000191967 Staphylococcus aureus Species 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 208000022292 Tay-Sachs disease Diseases 0.000 description 1
- 229920004890 Triton X-100 Polymers 0.000 description 1
- 239000013504 Triton X-100 Substances 0.000 description 1
- 108091023045 Untranslated Region Proteins 0.000 description 1
- 208000001910 Ventricular Heart Septal Defects Diseases 0.000 description 1
- JLCPHMBAVCMARE-UHFFFAOYSA-N [3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[3-[[3-[[3-[[3-[[3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-[[5-(2-amino-6-oxo-1H-purin-9-yl)-3-hydroxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxyoxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(5-methyl-2,4-dioxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(6-aminopurin-9-yl)oxolan-2-yl]methoxy-hydroxyphosphoryl]oxy-5-(4-amino-2-oxopyrimidin-1-yl)oxolan-2-yl]methyl [5-(6-aminopurin-9-yl)-2-(hydroxymethyl)oxolan-3-yl] hydrogen phosphate Polymers Cc1cn(C2CC(OP(O)(=O)OCC3OC(CC3OP(O)(=O)OCC3OC(CC3O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c3nc(N)[nH]c4=O)C(COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3COP(O)(=O)OC3CC(OC3CO)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3ccc(N)nc3=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cc(C)c(=O)[nH]c3=O)n3cc(C)c(=O)[nH]c3=O)n3ccc(N)nc3=O)n3cc(C)c(=O)[nH]c3=O)n3cnc4c3nc(N)[nH]c4=O)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)n3cnc4c(N)ncnc34)O2)c(=O)[nH]c1=O JLCPHMBAVCMARE-UHFFFAOYSA-N 0.000 description 1
- 230000003213 activating effect Effects 0.000 description 1
- 230000004913 activation Effects 0.000 description 1
- 125000000539 amino acid group Chemical group 0.000 description 1
- 238000004873 anchoring Methods 0.000 description 1
- 238000000137 annealing Methods 0.000 description 1
- 229960004405 aprotinin Drugs 0.000 description 1
- 238000013528 artificial neural network Methods 0.000 description 1
- 210000003719 b-lymphocyte Anatomy 0.000 description 1
- 239000011324 bead Substances 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 210000001124 body fluid Anatomy 0.000 description 1
- 239000010839 body fluid Substances 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- 238000010804 cDNA synthesis Methods 0.000 description 1
- 201000011510 cancer Diseases 0.000 description 1
- 238000007675 cardiac surgery Methods 0.000 description 1
- 210000000170 cell membrane Anatomy 0.000 description 1
- 239000006285 cell suspension Substances 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 235000013330 chicken meat Nutrition 0.000 description 1
- 229910052804 chromium Inorganic materials 0.000 description 1
- 239000011651 chromium Substances 0.000 description 1
- 210000001072 colon Anatomy 0.000 description 1
- 238000004440 column chromatography Methods 0.000 description 1
- 239000012050 conventional carrier Substances 0.000 description 1
- 239000012228 culture supernatant Substances 0.000 description 1
- 238000012258 culturing Methods 0.000 description 1
- 238000005520 cutting process Methods 0.000 description 1
- 230000001351 cycling effect Effects 0.000 description 1
- 230000009089 cytolysis Effects 0.000 description 1
- 230000007423 decrease Effects 0.000 description 1
- 238000004925 denaturation Methods 0.000 description 1
- 230000036425 denaturation Effects 0.000 description 1
- 238000002405 diagnostic procedure Methods 0.000 description 1
- 230000004069 differentiation Effects 0.000 description 1
- 229940079593 drug Drugs 0.000 description 1
- 238000001962 electrophoresis Methods 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 210000003743 erythrocyte Anatomy 0.000 description 1
- 239000013613 expression plasmid Substances 0.000 description 1
- 239000000284 extract Substances 0.000 description 1
- 239000012530 fluid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 102000037865 fusion proteins Human genes 0.000 description 1
- 108020001507 fusion proteins Proteins 0.000 description 1
- 238000002523 gelfiltration Methods 0.000 description 1
- 210000001654 germ layer Anatomy 0.000 description 1
- 208000015362 glutaric aciduria Diseases 0.000 description 1
- 229930004094 glycosylphosphatidylinositol Natural products 0.000 description 1
- 210000002216 heart Anatomy 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 201000010066 hyperandrogenism Diseases 0.000 description 1
- 210000002861 immature t-cell Anatomy 0.000 description 1
- 230000003053 immunization Effects 0.000 description 1
- 238000003119 immunoblot Methods 0.000 description 1
- 238000007901 in situ hybridization Methods 0.000 description 1
- 238000011534 incubation Methods 0.000 description 1
- 230000006698 induction Effects 0.000 description 1
- ZPNFWUPYTFPOJU-LPYSRVMUSA-N iniprol Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@H]2CSSC[C@H]3C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(N[C@H](C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC=4C=CC=CC=4)C(=O)N[C@@H](CC=4C=CC(O)=CC=4)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](C)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](C)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](CO)NC(=O)[C@H](CCCCN)NC(=O)[C@H](CC=4C=CC=CC=4)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCCN)NC(=O)[C@H](C)NC(=O)[C@H](CCCNC(N)=N)NC2=O)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CSSC[C@H](NC(=O)[C@H](CC=2C=CC=CC=2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H]2N(CCC2)C(=O)[C@@H](N)CCCNC(N)=N)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCC(O)=O)C(=O)N2[C@@H](CCC2)C(=O)N2[C@@H](CCC2)C(=O)N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N[C@@H]([C@@H](C)O)C(=O)NCC(=O)N2[C@@H](CCC2)C(=O)N3)C(=O)NCC(=O)NCC(=O)N[C@@H](C)C(O)=O)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@H](C(=O)N[C@@H](CC=2C=CC=CC=2)C(=O)N[C@H](C(=O)N1)C(C)C)[C@@H](C)O)[C@@H](C)CC)=O)[C@@H](C)CC)C1=CC=C(O)C=C1 ZPNFWUPYTFPOJU-LPYSRVMUSA-N 0.000 description 1
- 102000006495 integrins Human genes 0.000 description 1
- 108010044426 integrins Proteins 0.000 description 1
- 238000005342 ion exchange Methods 0.000 description 1
- 238000001155 isoelectric focusing Methods 0.000 description 1
- 210000003734 kidney Anatomy 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 230000004807 localization Effects 0.000 description 1
- 238000004020 luminiscence type Methods 0.000 description 1
- 230000001926 lymphatic effect Effects 0.000 description 1
- 238000013507 mapping Methods 0.000 description 1
- 230000013011 mating Effects 0.000 description 1
- 238000000691 measurement method Methods 0.000 description 1
- 208000030159 metabolic disease Diseases 0.000 description 1
- 201000000050 myeloid neoplasm Diseases 0.000 description 1
- 230000005305 organ development Effects 0.000 description 1
- 230000002611 ovarian Effects 0.000 description 1
- 230000002018 overexpression Effects 0.000 description 1
- 108040007629 peroxidase activity proteins Proteins 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000001885 phytohemagglutinin Effects 0.000 description 1
- 108010086652 phytohemagglutinin-P Proteins 0.000 description 1
- 230000003169 placental effect Effects 0.000 description 1
- 201000010065 polycystic ovary syndrome Diseases 0.000 description 1
- 102000054765 polymorphisms of proteins Human genes 0.000 description 1
- 229920002981 polyvinylidene fluoride Polymers 0.000 description 1
- 230000002265 prevention Effects 0.000 description 1
- 210000002307 prostate Anatomy 0.000 description 1
- 230000009257 reactivity Effects 0.000 description 1
- 238000003757 reverse transcription PCR Methods 0.000 description 1
- 239000012723 sample buffer Substances 0.000 description 1
- 239000013049 sediment Substances 0.000 description 1
- 238000000926 separation method Methods 0.000 description 1
- 210000002027 skeletal muscle Anatomy 0.000 description 1
- 210000000813 small intestine Anatomy 0.000 description 1
- 210000004989 spleen cell Anatomy 0.000 description 1
- 206010041823 squamous cell carcinoma Diseases 0.000 description 1
- 238000001356 surgical procedure Methods 0.000 description 1
- 208000011580 syndromic disease Diseases 0.000 description 1
- 230000009466 transformation Effects 0.000 description 1
- 238000003146 transient transfection Methods 0.000 description 1
- 201000011296 tyrosinemia Diseases 0.000 description 1
- 201000007972 tyrosinemia type I Diseases 0.000 description 1
- 210000004291 uterus Anatomy 0.000 description 1
- 201000003130 ventricular septal defect Diseases 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
- C07K14/70596—Molecules with a "CD"-designation not provided for elsewhere
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
Definitions
- the present invention relates to a newly identified polynucleotide encoding CDW108; an expression vector containing the polynucleotide; a transformant containing the expression vector; a method for producing CDwl08 recombinant protein; An antibody against the protein or a fragment thereof; an oligonucleotide capable of specifically binding to the polynucleotide; a pharmaceutical composition containing the polynucleotide, the oligonucleotide or the antibody and a fragment thereof as an active ingredient; A reagent for detecting CDwl08; and a kit for diagnosing CDwl08-related diseases.
- CDW108 is also called John-Milton-Hagen (hereinafter sometimes abbreviated as JH), human blood group antigen, and glycosylphosphatidylinositol (hereinafter abbreviated as GPI).
- JH John-Milton-Hagen
- GPI glycosylphosphatidylinositol
- CDwl08 acts on the development and activation of lymphocytes (reference numbers: 3-7).
- CDwl08 may be involved in some way in HIV-1 infection (Ref. No. 8).
- An object of the present invention is to provide a means for elucidating the molecular characteristics and biological functions of CDW108, and a means for applying to CDW108-related diseases and the like. That is, the gist of the present invention is:
- a polyamino acid sequence comprising an amino acid sequence having a substitution, deletion, addition or insertion in at least one kind of amino acid in the amino acid sequence at positions 47 to 647 of SEQ ID NO: 1;
- a polynucleotide comprising, in at least one of the nucleotide sequences described in any of (a) to (c), a nucleotide sequence having a substitution, deletion, addition or insertion in at least one base;
- polynucleotide selected from the group consisting of polynucleotides comprising a polynucleotide capable of hybridizing under stringent conditions with the polynucleotide of any one of (a) to (e), wherein A polynucleotide encoding a polypeptide having an effect of 08;
- a pharmaceutical composition comprising, as an active ingredient, the polynucleotide according to (1) or the oligonucleotide according to (8);
- a reagent for detecting CDwl08 comprising the polynucleotide according to (1) or the oligonucleotide according to (7),
- a reagent for detecting CDW108 comprising the antibody or the fragment thereof according to (6);
- a kit for diagnosing a CDwl08-related disease comprising the CDwl08 detection reagent according to the above (1 2) or (13);
- FIG. 1 shows the nucleic acid sequence of CDwl08 cDNA and the deduced amino acid sequence.
- the N-terminal 20-mer peptide from position H47 to position R66 and the PGI anchor motif from position A648 to position H666 are underlined. Putative N-linked glycosylation sites and RGD cell adhesion sequences are also underlined.
- FIG. 2 is a view following FIG. 1 showing the nucleic acid sequence of CDwl08 cDNA and the deduced amino acid sequence.
- FIG. 3 is a diagram showing the molecular structure of CDwl08. The numbers indicate amino acid residues. Closed circles indicate putative N-linked glycosylation sites.
- Fig. 4 shows the results of FACScan analysis of CDwl08 transfectants. TE-9 cells were prepared by temporarily transfecting CDwl08 cDNA (TE-9 / ZH5.11) or control antisense sequence (TE-9 / ZH5 .23). HPB-ALL cells and transfectants treated or untreated with PI-PLC were stained with FITC-conjugated anti-CDwl08 monoclonal antibody and analyzed by FACScan.
- FIG. 5 is a diagram showing chromosome mapping of the CDwl08 gene. This is the result of amplifying genomic DNA from PBMC by PCR using KS205S primer-1 and KS357A primer. The amplified 459-bp fragment contained a 298-bp intron.
- FIG. 6 shows the results of the same fragment amplified from the Gene Bridge-4 Radiation hybrid panel, hybridized with SSOP KS254S, and then dot-blotted on a nitrocellulose filter.
- FIG. 7 is a diagram showing the location of the CDwl08 gene on the chromosome.
- FIG. 8 shows the deduced amino acid sequences of mouse and human CDwl08.
- the N-terminal signal peptide, RGD motif and GPI-anchor motif are underlined. Putative N-linked glycosylation sites are indicated by filled circles.
- FIG. 9 shows the results of Northern blot analysis of mouse CDwl08 mRNA in adult tissues.
- the upper panel shows the results of CDwl08 mRNA expression in various normal tissues of adult (12-week-old) BALB / c mice.
- the lower panel shows the results when using -actin as a control.
- FIG. 10 shows the results of Northern blot analysis of mouse CDwl08 mRNA during the fetal period.
- Panel A shows mRNA expression in whole embryo tissue 7-17 days after fertilization.
- Panel B shows mRNA expression in various fetal tissues.
- G3PD H mRNA is shown as a control.
- FIG. 11 shows the results of FACScan analysis of CDW108 expression in human thymocytes.
- Panel A shows that human thymocytes were treated with FITC-conjugated anti-CDW108 monoclonal antibody (mA b) shows the results of staining with PE-conjugated anti-CD3 mAb and analysis by FACScan.
- Panel B shows the results of staining the cells with FITC anti-CDwl08, PE anti-CD4 and Tricolor anti-CD8 mAb, and analyzing the expression of CDwl08 after gating on CD4 and CD8.
- Panel C shows the results of staining with FITC-anti-CDwl08, PE-anti-CD117, and chrome-anti-CD34 mAb, and analyzing the expression of CDwl08 after gating with CD34 and CD117.
- FIG. 12 shows the results of FACScan analysis of CDwl08 expression in human umbilical cord blood cells.
- Umbilical cord blood mononuclear cells were stained with FITC anti-CDwl08, PE anti-CD117, and cyclochrome anti-CD34 mAb, and CDwl08 expression was analyzed after gating with CD34 and CD117.
- the polynucleotide of the present invention encodes the CDwl08 protein (hereinafter, the CDW108 protein may be simply referred to as “CDwl08j”.)
- the polynucleotide of the present invention includes: (a) position 47 of SEQ ID NO: 1 A polynucleotide encoding a polypeptide comprising the amino acid of position 647 to 647;
- a polynucleotide comprising a nucleotide sequence having a substitution, deletion, addition or insertion in at least one base in the polynucleotide sequence of any of (a) to (c);
- polynucleotide according to any of (a) to (e) and a stringent condition;
- Such a polynucleotide can be obtained, for example, according to the description in the Examples below.
- the nucleotide sequence shown in SEQ ID NO: 1 contains an open reading frame (hereinafter, referred to as 0RF) corresponding to CDwl08 cDNA consisting of 1998 bp. Such ORF corresponds to nucleotides 156 to 195 of SEQ ID NO: 1.
- the CDwl08 cDNA encodes a peptide of 666 amino acids containing 46 signal peptides and 19 GPI anchor motifs.
- substitution, deletion, addition or insertion of a base may be a naturally occurring mutation or a mutation artificially introduced.
- naturally occurring mutation includes mutation of at least one type of residue through degeneracy.
- at least one means one or more or more.
- Means for artificially introducing mutations include, for example, those described in Molecular C1oning: A Laboratory Manual, 2nd edition, volume 1-3, Sambrook, J. et al., Cold Spring Harber Laboratory Press, New York (1989). Method.
- substitution, deletion, addition or insertion of a base is at least one kind, that is, one or more or more, and the polypeptide generated by the substitution, deletion, addition or insertion of such a base is Any polypeptide having the action of CDW108 may be used.
- substitution, deletion, addition or insertion of an amino acid may be a naturally occurring mutation or a mutation introduced artificially.
- the “substitution, deletion, addition or insertion” of an amino acid is at least one, that is, one or more or more, and a polypeptide having the substitution, deletion, addition or insertion of such amino acid.
- the polypeptide may be a polypeptide having the effect of CDwl08.
- Polynucleotides that can hybridize under stringent conditions are described in Molecular Cloning: A Laboratory Manual, 2nd edition, volume 3, Sambrook, J. et al., Clod Spring Harbor Laboratory Press, New York (1989). It can be manufactured by the method described above. "Possible to hybridize under stringent conditions” means, for example, after heating at 42 ° C in a solution of 6X SSC, 0.5% SDS and 50% formamide, 0.1X This indicates that a positive hybridizing signal is still observed under the conditions of washing at 68 ° C in a solution of SSC and 0.53 ⁇ 4SDS.
- the polynucleotide of the present invention may be DNA or RNA.
- CDW108 mRNA is shown to be expressed in activated PBM spleen, thymus, testis, placenta and brain, but not in other examined tissues. Moreover, radiation hybrid mapping suggests that the CDW108 gene is located in the middle of the long arm of chromosome 15 at 15q23-24. Furthermore, a contribution of CDW108 in the positive selection stage in the thymus during lymphocyte development, especially T cell development, is suggested.
- Such examples include the mouse CDwl08 gene having the nucleotide sequence of SEQ ID NO: 7 and the amino acid sequence of SEQ ID NO: 7 and the amino acid sequence of SEQ ID NO: 8 and the mouse CDW108 protein.
- the mouse CDwl08 mRNA expression is expressed in the brain, thymus, testis, and lung.
- the mouse CDwl08 mRNA size is about 3.5 kb, which is almost the same as the human CDwl08 mRNA size.
- high expression of mRNA for mouse CDwl08 is found not only in tissues of mature mice but also in the very early stage after fertilization, especially in whole embryo mice at 7 days of age.
- CDW108 mRNA expression once decreases in 11-day-old fetuses and then increases in 15- to 17-day-old fetuses.
- the polynucleotide of the present invention can be used for production of a recombinant protein of CDwl08 described below.
- the polynucleotide of the present invention can be used for controlling the expression of CDW108 by being introduced into cells, and can also be used as a research reagent for in situ hybridization, etc.
- the expression vector of the present invention contains the polynucleotide of the present invention.
- the vector used in the expression vector of the present invention can be selected according to the cell used as the host cell.
- the host cell is an Escherichia coli cell
- examples of the vector include a plasmid vector such as pUC118, pUC119, pBR322, pCR3, and pCMVSPORT; and a phage vector such as ⁇ and Agt11.
- examples of the vector include pYES2 and pYEUra3 in the case of yeast, and include pAcSGHisNT-A in the case of insect cells, and pKCR in the case of animal cells. , P EFBOS, c DM8, p CEV 4 and the like.
- Such a vector may optionally have factors such as an inducible promoter, a selection marker gene, and an evening monitor.
- an expression vector for efficiently expressing the CDwl08 gene is prepared.
- a GST (glutathione S—transferase) fusion with the appropriate promoter (lac, tac, trc, trp, CMV, etc.) to function in the host cell is required.
- the DNA fragment containing the CDwl08 gene may be inserted into a protein vector (eg, PGEX4T) or an expression vector (eg, pCDNA3.l Kyc-His) having a Tag (Myc, HisA) sequence.
- an appropriate host for example, E. coli BL21 strain, DH5 strain or COS-7 cell, etc.
- the transformant thus obtained is also included in the present invention.
- Host cells include E. coli cells, yeast cells, animal cells, insect cells, and the like.
- Escherichia coli, Escherichia coli K-12 strains include the HB101 strain, the C600 strain, the JM109 strain, the DH5 strain, the DH10B strain, the XL-BlueMRF 'strain, and the T0P1OF strain.
- yeast cells include Saccharomyces cerevisiae.
- Animal cells include L, 3T3, FM3A, CHO, COS, Vero, HeLa and the like.
- Insect cells include s ⁇ 9.
- a transformant can be obtained by introducing the expression vector of the present invention into a host cell.
- the expression vector can be introduced into a host cell by a conventional method described in the aforementioned Molecular Cloning: A Laboratory Manual, 2nd edition.
- One feature of the method for producing a CDwl08 recombinant protein of the present invention is to use the transformant.
- Conditions for culturing the transformant can be appropriately selected depending on the cell used and the vector used for the expression vector. For example, when a vector having a motor capable of inducing IPTG is used as a vector, expression of the CDwl08 recombinant protein can be induced by induction with IPTG during culture.
- the expressed CDwl08 recombinant protein can be purified by a suitable combination of centrifugation, gel filtration, ion exchange column chromatography, affinity chromatography, etc., according to a conventional purification method.
- the vector used in the expression vector is a vector that can produce a fusion protein of the target protein with another polypeptide such as glutathione-S-transferase, His-tag, etc.
- another polypeptide such as glutathione-S-transferase, His-tag, etc.
- the CDW108 recombinant protein obtained by the production method of the present invention contains the amino acid sequence represented by amino acids 47 to 647 of SEQ ID NO: 1 of SEQ ID NO: 1. .
- the CDwl08 recombinant protein obtained by the production method of the present invention comprises at least one residue in the amino acid sequence at positions 47 to 647 of SEQ ID NO: 1. It may be a polypeptide comprising an amino acid sequence having a substitution, deletion, addition or insertion in the group.
- CDW108 has a membrane-anchored form, which has an approximate molecular weight of 68-kDa for a form that is not glycosylated with 601 amino acids.
- An RGD (Arg-Gly-Asp) cell adhesion sequence and five N-glycosylation sites are present in the membrane force form.
- Analysis of CDwl08 cDNA transfectants by flow cytometry and immunoprecipitation confirms that the cloned cDNA encodes the native form of CDW108.
- the antibody or fragment thereof of the present invention is directed against the CDwl08 recombinant protein.
- Such an antibody or a fragment thereof can be prepared by a conventional method described in, for example, Antibodies; A Laboratory Manua 1, Lane, H. D. et al., Edited by Cold Spring Harber Laboratory Press, New York 1989.
- the antibody may be a polyclonal antibody or a monoclonal antibody.
- the antibody can be obtained by using the CDW108 recombinant protein and immunizing animals such as egrets, chickens and mice by a conventional method.
- animal "boosts" can be provided by the same protein or fragment thereof.
- Antibodies or fragments thereof can be purified by affinity chromatography, screening of cDNA libraries, immunological diagnostics [eg, immunoblotting, radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), Fluorescence or luminescence measurement method, etc.] and pharmaceuticals.
- immunological diagnostics eg, immunoblotting, radioimmunoassay (RIA), enzyme-linked immunosorbent assay (ELISA), Fluorescence or luminescence measurement method, etc.
- the oligonucleotide of the present invention is an oligonucleotide that can specifically bind to the polynucleotide of the present invention.
- Such an oligonucleotide can provide a probe which can be used for hybridization or a primer which can be used for PCR or the like.
- the presence or absence of the gene encoding CDwl08 and the presence or absence of the gene encoding CDwl08 can be determined in a mammal, specifically, a human, using the oligonucleotide of the present invention.
- what type of CDwl08 is present by the oligonucleotide of the present invention And what role each type plays in the cell and its processes, respectively.
- the length of the oligonucleotide of the present invention can be appropriately selected according to the purpose.
- primers it is usually 8 to 170 bases, preferably 13 to 130 bases, and in the case of primers, it is usually 8 to 50 bases, preferably 15 to 35 bases.
- the probe or primer can be usually synthesized chemically using a synthesizer, enzymatically synthesized using DNA polymerase I (Klenow fragment), or prepared by the PCR method.
- oligonucleotide capable of specifically binding refers to a nucleic acid having a Tm value according to the purpose, as described in the aforementioned Molecular Cloning: A Laboratory Manual, 2nd edition.
- the present invention further provides a pharmaceutical composition having the polynucleotide or the oligonucleotide of the present invention as an active ingredient and a pharmaceutical composition having the antibody of the present invention or a fragment thereof as an active ingredient. Since such a pharmaceutical composition contains the polynucleotide, oligonucleotide, antibody or fragment thereof of the present invention, it can suppress or enhance the action of CDW108. Therefore, such a pharmaceutical composition can be used for the prevention and treatment of diseases such as HIV-1 infection, which are suggested to be involved in CDwl08.
- the content of the polynucleotide, oligonucleotide, antibody or fragment thereof of the present invention in such a pharmaceutical composition may be an amount sufficient to control the function of CDW108. Further, the pharmaceutical composition may appropriately contain conventional carriers, excipients, auxiliaries and the like.
- Examples of the method for detecting CDwl08 of the present invention include a method for detecting a nucleic acid encoding CDW108 or a method for detecting CDwl08 protein itself as a detection target.
- One major feature of the method for detecting a nucleic acid encoding CDW108 is to use the polynucleotide or the oligonucleotide of the present invention.
- As a method for detecting the CDW108 protein itself the antibody of the present invention or a fragment thereof is used. Is one major feature.
- detection may be performed using the formation of a hybrid between the nucleic acid and the polynucleotide or oligonucleotide of the present invention as an index.
- Hybridization can be detected by conventional hybridization techniques.
- Test samples include, for example, sections of mRNA tissue samples (transferred onto a filter), cDNA synthesized from mRNA, and gene DNA. Such samples may be treated appropriately to detect hybrid formation. Can be applied as appropriate.
- the detection can be carried out by an antigen-antibody reaction between the CDW108 protein and the antibody of the present invention or a fragment thereof.
- detection can be performed by the same method as the immunological diagnostic method.
- Test samples include cells, tissue specimen sections, cell or tissue extracts, serum or plasma, other body fluids, recombinant proteins, culture supernatants, and the like. Can be appropriately performed.
- the reagent for detecting CDwl08 of the present invention is suitable for the method for detecting CDW108 of the present invention, and the reagent for detection containing the polynucleotide or the oligonucleotide of the present invention and the reagent for detecting the antibody or a fragment thereof of the present invention. Is mentioned.
- the content of the polynucleotide, the oligonucleotide, or the antibody or a fragment thereof in the CDwl08 detection reagent can be appropriately set within a range in which CDwl08 can be detected according to a test sample, a purpose, and the like described below.
- Such a reagent for detecting CDwl08 may appropriately contain a reagent used for detection (eg, a labeling substance, a buffer solution, etc.).
- a reagent used for detection eg, a labeling substance, a buffer solution, etc.
- the kit for diagnosing a CDW108-related disease of the present invention is useful for diagnosing a disease in which the involvement of CDwl08 is suggested, and has one major feature of containing the reagent for detecting CDwl08 of the present invention.
- the kit for diagnosing a CDwl08-related disease of the present invention comprises a reagent for collecting a test sample, a reagent for bringing the test sample into a state suitable for detection, and a control substance serving as a diagnostic index. You may contain suitably.
- the test sample is the same as that described above.
- the present invention will be described in more detail with reference to Examples, but the present invention is not limited to these Examples and the like.
- PHA phytohemagglutinin
- PBMC Human peripheral blood mononuclear cells: hereinafter abbreviated as PBMC
- PBMC mouse peripheral blood mononuclear cells
- KS-2 IgG2a
- H105 IgM
- PBMC peripheral blood mononuclear cells
- PBMC peripheral blood mononuclear cells
- HPB-ALL T cells
- NALM-6 B cells
- esophageal cancer cells TE9 Ref. No. 9
- the cells (1 ⁇ 10 7 ) were washed twice with PBS according to the method described in the literature (10), and 37 MBq of Na 125 I (IMS-30; Amersham, Arlington Heights, Ill.) By iodination with lact peroxidase. IL). After iodination, the cells are washed three times with PBS, and incubated at room temperature for 10 minutes with 1 ml of lysis buffer (50 mM Tris-HCl, H 7.5, 150 m NaCl, The cells were dissolved in 1% Triton X-100, 1 mM EDTA, 1 mM PMSF, 10 / g / ml aprot inin, 0.02% NaN 3 ).
- lysis buffer 50 mM Tris-HCl, H 7.5, 150 m NaCl
- CDW108 molecule according to the method of the previous literature (10), wherein, after immunoprecipitated with Tri ton-XlOO solubilized HPB-AL L cells (109 cells and equivalents) from the monoclonal antibody KS- 2, two-dimensional gel They were separated by electrophoresis (isoelectric focusing and SDS-PAGE). After separation, the appropriate protein spots are electrophoretically transferred to a PVDF membrane (Bio-Rad, Hercules, Calif.) And automated protein sequencer (477A, PE Applied Biosystems, Foster City, CA). Processed.
- Example 5 cDNA Cloning and CDwl 08 Sequencing
- a partial cDNA fragment (60 bp) of the CDW108 gene encoding N-terminal protein was amplified in HPB-ALL cells by RT-PCR. Furthermore, the PCR product was cloned with the plasmid vector pCRI I using the TA cloning system (Invitrogen, Carsbad, CA). The nucleic acid sequence of the cloned cDNA fragment was determined using an automatic DNA sequencer (AL Fexpress DNA sequencer, Pharmacia, Uppsala, Sweden). A pair of primers (K1 and K8) increased the 60 bp CDwl08 cDNA fragment. The amino acid sequence deduced from the cDNA fragment corresponded to 19 amino acids among the 20 N-terminal amino acid sequences.
- Synthetic 25-mer oligonucleotides that corresponded to the amplified sequence were used as probes and primers for the following sequencing from the cDNA library.
- KS-2gt 5'-ATCTTCGCCGTCTGGAAAGGCCATG-3 '(SEQ ID NO: 4)
- the cDNA library of HPB-ALL cells was screened using the Gene Trapper TM cDNA positive selection system (GIBCO-BRL) using KS-2gt as a probe or primer.
- a cDNA library was created using the SuperScriptT TM plasmid system (GIBCO-BRL) for cDNA synthesis and plasmid cloning.
- a cDNA library was prepared using an oligo (dT) Not I primer and ligated to a Sal I adapter. After cutting with Not I, the cDNA library is sized to remove excess adapter and ligated to the Not I / Sal I cleavage site of the plasmid expression vector -PCMVSP0RT2.0 (GIBCO-BRL) in one direction. did.
- Example 6 Transient transfection and flow cytometry
- TE9 cells (4 ⁇ 10 5 cells) were pre-cultured for 18 hours in 6-well plates using RPMI 1640 medium containing 10% FCS. Cells are rinsed twice with PBS and transformed with 2 g of pCR3-ZH5.11, PCR3-ZH5.23 or pCR3-ICAM-1 and 10 l ⁇ Lipofectoarain (GIBCO-BRL, Gaitherrsburg, MD) did. Cell surface expression of CDwl08 or CD54 (ICAM-1) was confirmed two days after the above transformation. Cells (2 ⁇ 10 5 ) were stained with FITC-conjugated anti-CDwl08 antibody (KS-2) or anti-CD54 antibody (YH370) for 30 minutes on ice.
- KS-2 FITC-conjugated anti-CDwl08 antibody
- YH370 anti-CD54 antibody
- KS205S 5'-CACGGTGAATATCGGCTCC-3 '(SEQ ID NO: 5)
- the PCR product was blotted on a nitrocellulose filter and incubated at 54 ° C for 2 hours in hybridization buffer (3 M tetra-methyl ammonium chloride (TMAC), 50 mM Tris-HCl (pH 8.0). ) was 2 mM EDTA, specific 3 2 to P-terminal label sequence Haiburidizu to 0. 1% SDS and 5 x Denhardt 's solution] among oligonucleotide probes KS254S (393-409). After the incubation, the filter was washed at 58 ° C with a TMAC solution (a solution obtained by removing the 5X Denhardt's solution from the hybridization buffer), and then subjected to autoradiography.
- TMAC tetra-methyl ammonium chloride
- the mouse cDNA clone AA260340 showed the highest homology with the human CDwl08 gene, so that the AA260340 is a truncated mouse homolog of the human CDwl08 gene. That was decided. Therefore, AA260340 was used as a probe for cloning the mouse CDwl08 gene.
- AA260340 was obtained from Genome Systems (St. Louis, MO). The 1.2 kbp insert fragment of this clone (AA260340) was cut out with EcoRI, and the fragment was separated by agarose gel electrophoresis.
- the procedure for colony hybridization is as follows: A total of 1 ⁇ 10 6 colonies were transferred to a nylon membrane (trade name: Hybond-N +, manufactured by Amersham), and the obtained membrane was subjected to [ 32 P] - 7% with the labeled fragments SDS-1 ra EDTA -0.5 M Ch urch 's phosphate buffer (0.25 M Na 2 HP0 4, pH7.2) in with one ⁇ incubated at 65 ° C was Haiburidizu, Then, the cells were washed at 65 ° C with 1% SDS-40 mM Church's phosphate buffer.
- nucleotide sequences of both strands of the cloned cDNA were determined using an automatic DNA sequencer (trade name: ABI PRISM 377 DNA Sequencer, PE Applied Biosystems, Foster City, CA). The obtained nucleotide sequence is shown in SEQ ID NO: 7, and the amino acid sequence deduced from the nucleotide sequence is shown in SEQ ID NO: 8.
- SEQ ID NO: 7 The obtained nucleotide sequence is shown in SEQ ID NO: 7
- amino acid sequence deduced from the nucleotide sequence is shown in SEQ ID NO: 8.
- RNA samples (12 weeks old) BALB / c mice were obtained from SLC (Hamamatsu, Japan). Total RNA was extracted from various tissues of mature mice using RNAzol B (Cinna / Biotech, Houston, TX). RNA extraction and isolation were performed according to the manufacturer's instructions. The RNA sample was subjected to formaldehyde agarose gel electrophoresis. (Hybond-N +).
- Example 10 Mouse Expression of CDW108 mRNA in Fetal Stage
- ICR mice were obtained from SLC (Hamaniatsu, Japan). From various tissues of a fetus (age 7 to 17 days after fertilization) and a newborn mouse (within 1 day after birth), RN Azol B Cinna / Biotech Co., Houston, TX) was used to perform the same procedure as in Example 9 above. RNA was extracted. Then, the RNA sample was subjected to formaldehyde agarose gel electrophoresis, and then transferred to a nylon membrane (trade name: Hybond-N +).
- Human thymocytes (1 ⁇ 10 6 ) were stained with FITC-conjugated anti-CDW108 monoclonal antibody (raAb) or PE-conjugated anti-CD3 mAb on ice for 30 minutes. After staining, wash with PBS, 1% After fixation with formaldehyde-PBS, analysis was performed by FACScan flow cytometry (Becton-Dicksonson) using Lysis II software (Becton-Dickinson, ountainview, CA) (Fig. 11 panel).
- human thymocytes (1 ⁇ 10 6 ) were stained with FITC anti-CDwl08, PE anti-CD4 and anti-CD8 mAb on ice for 30 minutes, and further treated with Trikara-conjugated streptavidin (CALTAG, Burl ingame, CA). After staining for 20 minutes on ice, CDW108 expression was analyzed by FACScan after gating with CD4 and CD8 (Fig. 11, panel B). Similarly, human thymocytes were stained with FITC anti-CDwl08, PE anti-CD117, and chromium anti-CD34 mAb, and CDwl08 expression was analyzed after gating with CD34 and CD117 (Fig. 11 panel C). ).
- the anti-human mAb KS-2 (anti-CDwl08), Nu-T3 (anti-CD3), NuTh / i (anti-CD4) and mAb Nu-Ts / c (anti-CD8) were purchased from Kurume University School of Medicine. Cyc CJ-conjugated anti-CD34 monoclonal antibody (mAb) and phycoerythrin (PE) -conjugated anti-CD117 (c-ki OmAb), previously prepared, were obtained from PharMingen (San Diego, CA). Piotin-conjugated anti-CD8 T8) was obtained from Coulter Project unotech (Westbrook, ME).
- the human CDwl08 cDNA clone was prepared from a leukemic T cell line HPB-ALL.
- the Smid library was screened and identified using an oligonucleotide probe Z primer encoding the N-terminal peptide.
- the resulting 1-kbp cDNA fragment was used as a probe to screen other HPB-ALL phage libraries—and human placenta libraries—to obtain longer cDNA clones.
- the cDNA sequence of the longest clone, ZH5 obtained from the HPB-ALL library shows a 1998 bp open reading frame and encodes a protein consisting of 666 amino acids below the Kozak motif ( Figures 1 and 2).
- the open reading frame contains an N-terminal signal peptide, an extracellular domain of 46 amino acids and 601 amino acids, followed by a C-terminal GPI anchor motif (Ref. No. 13).
- the C-terminal 3 residues consist - - (Hs 6 6 L 6 5 1) (A 6 4 8 S 6 5 0) cluster followed hydrophobic 16 residue of. Therefore, A 6 4 8 are called Omegasai bets may be anchored added.
- the molecular weight after cleavage with the GPI anchoring enzyme was 68-kDa.
- the RGD (Arg-Gly-Asp) sequence identified as a fibronectin cell adhesion sequence (Ref. Nos.
- CDwl08 was not expressed on the cell surface (FIG. 4).
- CD54 ICA-1
- ICAM-1 transfectants was not affected by PI-PLC treatment.
- the expression of CDwl08 in the transfectant was confirmed by immunoprecipitation analysis of the transfectant.
- CDwl08 mRNA size was approximately 3.5-kDa, and the same size was confirmed in PHA-activated PBMC, but inactive PBMC. And NALM-6 were not confirmed.
- the mismatch between the size of the mRNA and the size of the cloned cDNA was suggested to be due to the presence of an approximately 800-bp unspecified sequence within the 5 'and / or 3' end untranslated regions.
- CDwl08 mRNA expression in normal tissue panels was also analyzed by Northern blotting. High expression of CDwl08 mRNA was observed in placenta, testis and spleen, and weak expression was detected in brain and thymus.
- CDW108 plays an important role not only in the thymus but also in other organs.
- a 449-bp fragment of genomic DNA isolated from PBMC was amplified by PCR using KS205S and KS357A (Fig. 5).
- the PCR product contained a 298-bp intron, consistent with the GT-AG rule (ref: 18).
- a faint band but the same size PCR product was amplified from genomic DNA from hamster A23 cells under identical conditions.
- the PCR product from the radiation hybrid panel was dot-blotted and then hybridized with a sequence specific for the oligonucleotide probe KS254S. This probe hybridized with the product from genomic DNA from human HFL cells (Fig. 6, last column, third column from the right), but hybridized with the product from genomic DNA from hamster A23 cells. ( Figure 6, last column, second column from right).
- the CDwl08 gene is located in the middle of chromosome 15 and 5.23 centiray away from the WI-6247 marker gene, according to a data-based analysis for radiation hybrid mating. This region corresponds to the conventional 15q23-24 (Fig. 7). This site has been identified in several ovarian syndromes such as polycystic ovary syndrome with hyperandrogenemia, Tay-Sachs disease, GM-2 ganglionidosis, HexA pseudodeficiency, type I IA glutaric aciduria and type I tyrosinemia. It is close to genes associated with metabolic diseases (Ref. No. 19). Therefore, it will be important to study the involvement of the CDW108 gene in the pathogenesis or pathogenesis of these diseases. 5) Mouse CDwl08
- the resulting cDNA clone (335A1) contained a 2,538 bp insert containing a 1,992 bp open reading frame. It was deduced from the nucleotide sequence of such an open reading frame that it encoded 664 amino acids.
- Mouse CDwl08 cDNA has a high homology of 88.0% at the nucleic acid level and 89.3% at the amino acid level with human CDwl08, and particularly has an N-linked glycosylation site (the amino acid sequence in FIG. 8). , 154, 256, 328 and 600-position) and RGD (Arg- Gly- Asp) cell attachment sequence (R 2 6 5 - D 2 6 Ma) were conserved all between human h CDwl 08 and mouse CDwl08.
- the nucleotide sequence of mouse CDW108 was reported as mouse semaphorin K1 belonging to the semaphorin family involved in neural network development. However, the biological function of mouse semaphorin K1 / CDW108 has not been identified.
- CDwl08 mRNA expression in a panel of mature mouse tissues was analyzed by Northern blot (Fig. 9).
- CDW108 mRNA expression in adult mouse tissues was expressed in brain, thymus, testis and lung. With the exception of expression in the lung, the expression distribution was similar to that in human tissues.
- the mRNA size of mouse CDW108 was about 3.5 kb, which was almost the same as that of human CDwl08 mRNA.
- CDwl08 mRNA expression was once reduced in 11-day-old fetuses, and then increased in 15-17 day-old fetuses.
- the 7-day-old fetus was composed of germ layer structures and organogenesis was not initiated at this stage. At 11 days of fertilization, major organs were seen. However, no lymphatic organs such as thymus and spleen were found. The lymphoid organ was found 12 days after fertilization.
- the two stages of CDW108 expression in the fetus suggested that CDW108 plays an important role in early embryogenesis and late development in the fetus.
- CDwl08 raRNA was found in the fetal thymus after 14 days of age and in the lung and brain (Fig. 10 panel B). Expression of CDwl08 in the thymus was found in 14-18 day old fetuses, neonates (Pl in FIG. 10 panel B, P1) and adult mice, with maximal expression found in 14 day old fetuses. In the spleen, CDwl08 was expressed only in 14- and 16-day-old fetuses, and its expression disappeared after 18 days after fertilization. In contrast, CDW108 expression increased in brain and lung during embryonic development.
- CDW108 expression was not observed in the entire fetal period, neonatal, and adult mouse liver. These results suggest that CDW108 is expressed on immature T cells in the thymus and on certain immature lymphocyte cells found in the early stages of fetal spleen in lymphoid organs.
- CDwl08 was expressed on about 15% of the thymus, especially on CD3 du M or CD3- cells, as shown in Fig. 11. Was.
- the expression of CDW108 in the thymus subset was analyzed using FITC-CDwl08, PE-CD4 and Tricolor-CD8.
- CDW108 was remarkably expressed in the CD4 + CD8 + (double positive) subset. That is, more than 20% of the double positive subsets expressed CDwl08, and the other subsets (CD4 or CD8 single positive and double negative) hardly expressed CDW108.
- CD4CD8 double negative cells are first stem cells It expresses a cell marker, CD34, and the expression of CD34 disappears during T cell development in the thymus.
- CD117 c-kit
- CD117 is also known as a stem cell marker, but is also expressed on some immature cells of the thymus.
- FIG. 11 the expression of CDW108 in the CD34 and CD117 subsets was examined (FIG. 11). It was prominently expressed in both thymic CD34 + CD117 + and CD34-CD117 + groups. The process of differentiation of these groups in T cell development represents a stage of thymic positive selection. Therefore, CDwl 08 is likely to play an important role at this stage.
- CD34 + stem cells including CD34 + CD117 + and CD34 + CD117 ⁇ cells in cord blood significantly expressed CDW108 (89.9% and 80.1%, respectively).
- Bobol is, K.A., Molds, J.J., and Telen, .J. 1992.Isolation of the JMH antigen on a novel phosphatidylinositol-1 inked human membrane protein.Blood 79: 1574.
- lymphocyte function-associated antigen l (LFA-l) on an adenocarc. inoma cell line is a distinct molecule from FA-1 on leukocytes.
- the URL is http://www3.ncbi.nlni.nih.gov/omim/ Industrial availability
- the polynucleotide, the CDwl08 recombinant protein and the like of the present invention are useful for elucidating the biological function of CDwl08 and diseases associated with the CDW108 gene.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Organic Chemistry (AREA)
- Biochemistry (AREA)
- Genetics & Genomics (AREA)
- Gastroenterology & Hepatology (AREA)
- Toxicology (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- General Health & Medical Sciences (AREA)
- Zoology (AREA)
- Medicinal Chemistry (AREA)
- Molecular Biology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Cell Biology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Peptides Or Proteins (AREA)
- Preparation Of Compounds By Using Micro-Organisms (AREA)
Description
Claims
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
AU54430/99A AU5443099A (en) | 1998-08-26 | 1999-08-25 | Gene encoding cdw108 |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP23968798A JP2002223758A (ja) | 1998-08-26 | 1998-08-26 | CDw108をコードする遺伝子 |
JP10/239687 | 1998-08-26 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2000012700A1 true WO2000012700A1 (fr) | 2000-03-09 |
Family
ID=17048428
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/JP1999/004571 WO2000012700A1 (fr) | 1998-08-26 | 1999-08-25 | GENE CODIANT CDw108 |
Country Status (3)
Country | Link |
---|---|
JP (1) | JP2002223758A (ja) |
AU (1) | AU5443099A (ja) |
WO (1) | WO2000012700A1 (ja) |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007308466A (ja) * | 2006-05-15 | 2007-11-29 | Boehringer Ingelheim Internatl Gmbh | サイトカイン媒介疾患の治療方法 |
-
1998
- 1998-08-26 JP JP23968798A patent/JP2002223758A/ja active Pending
-
1999
- 1999-08-25 WO PCT/JP1999/004571 patent/WO2000012700A1/ja active Application Filing
- 1999-08-25 AU AU54430/99A patent/AU5443099A/en not_active Abandoned
Non-Patent Citations (1)
Title |
---|
CAROLINE LANGE ET AL.: "New Eukaryotic Semaphorins with Close Homology to Semaphorins of DNA Viruses", GENOMICS, vol. 51, 1 August 1998 (1998-08-01), pages 340 - 350, XP002926148 * |
Cited By (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JP2007308466A (ja) * | 2006-05-15 | 2007-11-29 | Boehringer Ingelheim Internatl Gmbh | サイトカイン媒介疾患の治療方法 |
Also Published As
Publication number | Publication date |
---|---|
AU5443099A (en) | 2000-03-21 |
JP2002223758A (ja) | 2002-08-13 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR101507976B1 (ko) | 종양에서 특이적으로 발현되는 유전 산물 및 그의 용도 | |
US5316920A (en) | Lymphocyte activation antigen HB15, a member of the immunoglobulin superfamily | |
JP2006515318A (ja) | 特異的に発現する癌関連遺伝子、それによってコードされるポリペプチドおよびその使用方法 | |
JP2003199566A (ja) | レセプターチロシンキナーゼ標的タンパク質のcDNAクローニング方法及びhGRBタンパク質 | |
US20090214517A1 (en) | Compositions and methods of use for modulators of nectin 4, semaphorin 4b, igsf9, and kiaa0152 in treating disease | |
US7297493B2 (en) | Fibroblast growth factor receptor activating gene 1 and related compositions and methods | |
JP3779989B2 (ja) | リンパ抗原cd30 | |
JP2005503135A (ja) | 新規gタンパク質共役受容体およびそのdna配列 | |
WO2002062946A2 (en) | Identification of novel ms4a gene family members expressed by hematopoietic cells | |
US20060134751A1 (en) | Identification of novel MS4A gene family members expressed by hematopoietic cells | |
WO2000012700A1 (fr) | GENE CODIANT CDw108 | |
JP2003510053A (ja) | ヘパラナーゼ蛋白質ファミリーの1種、ヘパラナーゼ−2 | |
JP2003530109A (ja) | エルビンをコードする遺伝子及びその診断及び治療的使用 | |
US6683168B1 (en) | Genes and methods that modulate apoptosis | |
CA2399391A1 (en) | Trade molecules and uses related thereto | |
US6632617B1 (en) | Tumor-associated antigen | |
HUT70456A (en) | Cloning and expression of b-app-c100 receptor | |
WO2006082851A1 (ja) | エピグリカニン関連ムチン | |
AU2006200373B2 (en) | Novel tumor supressor encoding nucleic acid, PTX1, and methods of use thereof | |
JPH09252788A (ja) | ヒトムチン(muc8) | |
CA2420054A1 (en) | Novel tumor suppressor encoding nucleic acid, ptx1, and methods of use thereof | |
US20090018071A1 (en) | Epididymis-specific receptor protein | |
US20030166501A1 (en) | Mucin-related tumor marker | |
JPH11290083A (ja) | 新規蛋白質 | |
MXPA06009312A (es) | Ligandos de proteina para receptores nkg2d y ul16 y usos de los mismos |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KR KZ LC LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW SD SL SZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
122 | Ep: pct application non-entry in european phase | ||
NENP | Non-entry into the national phase |
Ref country code: JP Ref document number: 2000567687 Format of ref document f/p: F |